ClinVar Miner

Submissions for variant NM_052859.4(RFT1):c.1133A>G (p.Tyr378Cys)

gnomAD frequency: 0.00046  dbSNP: rs143232904
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia RCV000202827 SCV000258227 uncertain significance not specified 2015-06-17 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000765751 SCV000445561 uncertain significance RFT1-congenital disorder of glycosylation 2018-01-13 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Fulgent Genetics, Fulgent Genetics RCV000765751 SCV000897135 uncertain significance RFT1-congenital disorder of glycosylation 2022-02-10 criteria provided, single submitter clinical testing
Invitae RCV000765751 SCV001559818 uncertain significance RFT1-congenital disorder of glycosylation 2024-01-24 criteria provided, single submitter clinical testing This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 378 of the RFT1 protein (p.Tyr378Cys). This variant is present in population databases (rs143232904, gnomAD 0.07%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with autism spectrum disorder (PMID: 33023636). ClinVar contains an entry for this variant (Variation ID: 218826). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RFT1 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002515509 SCV003691432 uncertain significance Inborn genetic diseases 2021-11-19 criteria provided, single submitter clinical testing The c.1133A>G (p.Y378C) alteration is located in exon 11 (coding exon 11) of the RFT1 gene. This alteration results from a A to G substitution at nucleotide position 1133, causing the tyrosine (Y) at amino acid position 378 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.